

GEORGIA STATE BOARD OF PHARMACY

BOARD MEETING

September 14, 2011

Professional Licensing Boards

237 Coliseum Drive

Macon, GA 31217

Members Present:

Steve Wilson, President

Bill Prather, Vice President

Judy Gardner

Al McConnell

Ronnie Wallace

Tony Moye

Fred Barber

Members Absent:

Pat McPherson

Staff Present:

Lisa Durden, Executive Director

Janet Wray, Board Attorney

Rick Allen, GDNA

Melanie Bradley, Board Support Specialist

Visitors:

Dr. Jim Bartling

Fran Cullen

Scott Biddulph, Target

Ruth Thompson, TCSG

Kathryn Hornsby, TCSG

JD Banker, TCSG

Ken Borderding, Wilmer

Brian Robinson, Walgreens

Steve Wilson established that a quorum was present and called the meeting to order at 9:59 a.m.

Appointments – Open Session

1. Scotti Russell with National Association of Boards of Pharmacy appeared before the Board to present their services that could benefit the Board. The Board expressed interest in the CPE

monitoring service which provides an electronic system to verify continuing education credits required of pharmacists.

2. Ruth Thompson, JD Banker and Kathryn Hornsby with the Technical College System of Georgia appeared before the Board to discuss the 3:1 ratio and whether it applies to registered pharmacy technician students. Further, to seek Board endorsement for their pharmacy technician curriculum. The Board stated that all pharmacy technicians must be registered and that technicians so fall into the 3:1 ration. The Board also stated that they do not require technician to attend an educational based program or curriculum specifically for pharmacy technicians to be eligible for registration.

*Bill Prather made a motion, Judy Garland seconded, and the Board voted unanimously to enter into **EXECUTIVE SESSION** in accordance with O.C.G.A. §§43-1-19(h) 2 and 43-1-2(k) to review applications, deliberate on disciplinary matters, and to receive information on investigative reports. Voting in favor of the motion were those present who included Board members Al McConnell, Fred Barber, Ronnie Wallace, and Tony Moye.*

Appointments – Executive Session

1. E.C.G. appeared before the Board to discuss reinstatement of his Pharmacist license. A motion was made by Ronnie Wallace to reinstate the license under a Public Consent Order; Tony Moye seconded the motion, Fred Barber opposed, and the Board voted to reinstate the license under a Public Consent Order.
2. C.L.H. appeared before the Board to discuss reinstatement of her Pharmacist license. A motion was made by Judy Gardner to reinstate the license under a Private Consent Order; Bill Prather seconded the motion, Fred Barber opposed, and the Board voted to reinstate the license under a Private Consent Order.
3. Yvette A. King appeared before the Board to appeal the denial of her pharmacist reciprocity application. A motion was made by Bill Prather to require her to provide more information. Ronnie Wallace seconded the motion and the Board voted to require her to provide further information.
4. Debra A. Wheeler appeared before the Board to appeal the denial of her pharmacy technician registration. A motion was made by Ronnie Wallace to overturn the Board's previous decision and to approve her registration as pharmacy technician. Tony Moye seconded the motion and the Board voted unanimously in favor of the motion.
5. Eric D. Reddington appeared before the Board to discuss his application for pharmacist. A motion was made by Bill Prather to issue pharmacy license. Ronnie Wallace seconded the motion and the Board voted to issue pharmacy license.
6. K. W.C. appeared before the Board to discuss reinstatement of his Pharmacist license. A motion was made by Ronnie Wallace to reinstate the license under a Public Consent Order; Al McConnell seconded the motion and the Board voted to reinstate the license under a Public Consent Order.

7. Elizabeth Tidwell appeared before the Board to discuss her application for pharmacy technician registration. A motion was made by Tony Moye to register as pharmacy technician. Al McConnell seconded the motion and the Board voted to register as pharmacy technician.

Applications/Licensures

1. A.R. – Pharmacy Technician - Board recommended approval for registration.
2. C.M.B. – Pharmacy Technician - Board recommended approval for registration.
3. E.K.M. – Pharmacy Technician - Board recommended approval for registration.
4. G.G. – Pharmacy Technician - The Board recommended that she contact the Board again when her criminal charges are resolved.
5. N.V.B. – Pharmacy Technician - Board recommended denial of registration.
6. A.R.J. – Board recommended approval her application for pharmacy intern license.
7. L.A.S. – Pharmacy Intern - Board recommended an investigative interview.
8. L.K.P. – Board recommended approval her application for pharmacy intern license through December 2012.
9. M.S.M. – Board recommended denial his reciprocity application for pharmacist license.
10. T.M.T. – Board recommended approval his application for pharmacy intern license under a private consent order.
11. C.A.J. – Board recommended approval her request for an appearance to discuss reinstatement of her pharmacist license.
12. J.O.S. - The Board recommended denial his application for reinstatement for pharmacist license.
13. M.J.H. – Board recommended accepting her signed Consent Order.
14. M.G.L. – Board recommended approval her application for reinstatement of pharmacist license.
15. P.J.M. – Board recommended denial his request for appearance and instructed he file application for reactivation of pharmacist license.
16. G.R.R. – Board recommended suspension of Pharmacist license.
17. B.T.M. – Board recommended approval the wholesaler renewal application.
18. T.O. – Board recommended accepting her response to the Letter of Concern she was issued.
19. W. – Board recommended proceeding with their recommendations from the July meeting and issue \$5000 fine.
20. A.D.P. – Board recommended denial her request for waiver of application fee. Board recommended approval her application for reactivation of pharmacist license when the fee is paid.
21. B.M.C. – Board recommended approval her application for pharmacy intern license.
22. A.N.J. – Pharmacy Technician - recommended approval for registration.
23. V.N.W. – Pharmacy Technician - recommended approval for registration if her case is dismissed on 9/20/2011.
24. V.T.O. – Per Board Attorney Janet Wray, Board recommended approval her renewal application for pharmacist license.

25. E.F.R. – Board recommended that he will have to submit a complete application and meet all the requirements prior to the Board considering his request for reinstatement.
26. R.S.E. – Failed to renew in a timely manner and has submitted an application for reinstatement. The Board recommended sending a letter to the corporate offices/pharmacies regarding his unlicensed practice and to refer his case to the Attorney General’s office for a Consent Order with a \$5,000 fine for practicing unlicensed.

Attorney General’s Report:

Senior Assistant Attorney General, Janet B. Wray presented a status report including 20 open cases and 7 closed cases. The following consent orders were presented for acceptance:

- Natasha Gleaton – Public Consent Order
- M.J.H. – Private Consent Order
- G.J. – Private Consent Order for Reinstatement
- C.M. – Private Consent Order

Cognizant Report – Bill Prather, Cognizant Member

GDNA Case #A11-21 – The Cognizant Member recommended that Board send a letter of concern to the pharmacy and the pharmacist in charge regarding receiving controlled substances from an unlicensed wholesaler; maintaining proper records; and proper distribution practice.

GDNA Case #A11-21-B - The Cognizant Member recommended closing the case – no jurisdiction.

GDNA Case #A-29585 – The Cognizant Member recommended to table a report on this case since the Pharmacist in Charge has requested a separate interview with the Cognizant Member.

GDNA Case #A-29847 – The Cognizant Member recommended that Board send a letter of concern to the pharmacists and to the pharmacy regarding their failure to keep proper records and failure to properly supervise pharmacy technicians.

GDNA Case #A11-17 – The Cognizant Member recommended to table any decision until the investigative interview takes place.

GDNA Case #A-29792 and #A-29794 – The Cognizant Member recommend that Board send a letter of concern to the pharmacist and the pharmacy to be more vigilant in monitoring the inventory of controlled substances and reporting to DEA in a timely manner.

GDNA Case #t-30000 – Cognizant Member recommended to approve her pharmacy technician registration.

GDNA Case #A11-27 – Cognizant Member recommended to accept the signed Public Interim Consent Order.

GDNA Case #A11-26 – Cognizant Member recommended to accept the signed Private Interim Consent Order for Assessment.

GDNA Case #A11-23 – Cognizant Member recommended to accept the signed Public Interim Consent Order.

GDNA Case #A11-33 – Cognizant Member recommended to accept the signed Private Interim Consent Order.

GDNA Case #B-29725 – The Cognizant Member recommended a Private Consent Order with a \$500 fine each for pharmacist and pharmacy; pharmacist must also attend misfill school; and, pharmacist must submit written plan for correcting the problem.

GDNA Case #B-29751 - The Cognizant Member recommended closing the case – no violation.

GDNA Case #A-29758 – The Cognizant Member recommended an Investigative Interview.

GDNA Case #A-29764 – The Cognizant Member recommended a Consent Order and \$5000 fine.

GDNA Case #B-29765 – The Cognizant Member recommended a letter of concern regarding the failure to maintain proper records.

GDNA Case #B-29783 – The Cognizant Member recommended closing the case – no violation.

GDNA Case #B-29849 – The Cognizant Member recommended a Consent Order and \$5000 fine.

At the conclusion of **EXECUTIVE SESSION**, Ronnie Wallace made a motion to enter into **Open Session** to vote on the matters discussed in Executive Session and to conduct other Board business; Judy Gardner seconded the motion. Voting in favor of the motion were Bill Prather, Tony Moye, and Al McConnell. Fred Barber was no longer present at the meeting.

OPEN SESSION

Ronnie Wallace made a motion to approve the recommendations made in Executive Session; Judy Gardner seconded the motion. Voting in favor of the motion were Bill Prather, Tony Moye, and Al McConnell. Fred Barber was no longer present at the meeting.

The Board voted to accept the following signed Board orders:

A.D. – Private Interim Consent Order

David Bishop – Interim Consent Order

Timothy Scott Ramsey - Interim Consent Order

D.M.T. – Private Interim Consent Order

T.E.L. – Private Consent Order

J.A.H. – Private Consent Order

Ronnie Wallace made a motion to approve the minutes as amended from the August 17, 2011 Board meeting; Bill Prather seconded the motion. The Board voted to approve the minutes.

Executive Director Lisa Durden presented a list of licenses and registrations (2,416) that were issued from August 1-31, 2011. Bill Prather made a motion to ratify the list of licenses and registrations; Ronnie Wallace seconded the motion. The Board voted to ratify the licenses and registrations issued.

Bill Prather made a motion to post the revision of Rule 480-22-.12, and Tony Moye seconded the motion. The Board voted to post the revision of Rule 480-22-.12.

*NOTE: Struck through text is proposed to be deleted. Underlined text is proposed to be added.

480-22-.12 Requirements of Prescription Drug Orders as Issued by a Physician's Assistant (PA) or an Advanced Practice Registered Nurse (APRN) Licensed to Practice in the State of Georgia.

(1) Under O.C.G.A. § 43-34-103(e.1), a physician's assistant (PA) licensed by the Georgia Composite Board of Medical Examiners is permitted to issue a prescription drug order or orders for any dangerous drugs, as defined in O.C.G.A. § 16-13-71 without the co-signature of a supervising physician pursuant to the authority delegated by the PA's supervising physician and contained in the PA's job description.

(a) A PA cannot issue a prescription for any C-II, III, IV, or V controlled substance without having such prescription co-signed by his or her supervising physician, unless such PA has his/her own DEA number.

(b) Delegation of such authority shall be contained in the job description required by O.C.G.A. § 43-34-103(e.1). The delegating physician shall remain responsible for the medical acts of the PA.

(2) Nothing in this Rule, Title 16, Chapter 13 or Title 43, Chapter 34, shall be construed to create a presumption of liability, either civil or criminal, on the part of a pharmacist who in good faith fills a prescription drug order presented by a patient pursuant to this Rule.

(a) A pharmacist shall presume that the prescription drug order was issued by a PA duly licensed and qualified under Title 43, Chapter 34 to prescribe pharmaceutical agents.

(b) A pharmacist shall presume that the drug prescribed by the PA is a drug approved by the supervising physician in the PA's job description, unless the pharmacist has actual or constructive knowledge to the contrary.

(3) The PA shall only be authorized to exercise the rights granted by O.C.G.A. § 43-34-103(e.1) using a prescription drug order which includes the following:

(a) The name, address, NPI number, and telephone number of both the prescribing physician and the PA;

(b) The patient's name and address;

(c) The drug name, strength and quantity prescribed;

(d) The directions to the patient with regard to taking the drug;

(e) The number of authorized refills, if any;

(f) If applicable, The the DEA permit number of the supervising physician and or, if applicable, the DEA number of the PA; and

(g) Such prescription drug order form shall be valid only if signed by the physician's assistant and the following terminology appears on the prescription drug order: "This prescription authorized through (pre-printed name of the prescribing supervising physician, M.D. or D.O.) by (pre-printed name of the PA printed below the signature line, with such line bearing the signature of the PA), PHYSICIAN'S ASSISTANT"

~~(Physician's Assistant must be spelled out, not abbreviated as PA).~~

~~1. An example, which satisfies the requirements for both Controlled Substance and Dangerous Drug prescription drug order, is as follows: "This prescription authorized through O.C. Cornwallis, M.D. by, Physician's Assistant Jane Doe (pre-printed).~~

(4) Any prescription drug order form containing less information than that described in this subsection shall not be offered to or accepted by any pharmacist.

(5) Under O.C.G.A. § 43-34-26.3(e.1), an advanced practice registered nurse (APRN) who is recognized by the Georgia Board of Nursing as having met the requirements established by the Georgia Board of Nursing to engage in advanced nursing practice, is in good standing with the Georgia Board of Nursing, and who has entered into a nurse protocol agreement, approved by the Composite Board of State Medical Examiners, with a delegating physician is permitted to issue a prescription drug order or orders for any dangerous drug, as defined in O.C.G.A. § 16-13-71 without the co-signature of a delegating physician pursuant to the authority delegated by the APRN's delegating physician and contained in the APRN's nurse protocol.

(a) An APRN can issue a prescription drug order for any Schedule III, IV, or V controlled substance without having such prescription co-signed by his or her delegating physician, if such APRN has his or her own Federal Drug Enforcement Administration (DEA) number; An APRN has no authority to issue a Schedule I or II controlled substance prescription. If an APRN does not have their own federal DEA number, the prescription must be signed by the delegating physician.

(b) An APRN is not authorized to issue refills of any dangerous drug for more than 12 months from the date of the original order, except in the case of oral contraceptives, hormone replacement therapy, or prenatal vitamins which may be refilled for a period of 24 months. An APRN is not authorized to issue more than five (5) refills of any Schedule III, IV, or V controlled substance for more than six (6) months from the date of the original order.

(c) Delegation of such authority shall be contained in the nurse protocol required by O.C.G.A. § 43-34-26.3. The delegating physician shall remain responsible for the medical acts of the APRN.

(6) Nothing in this Rule, Title 16, Chapter 13 or Title 43, Chapter 34, shall be construed to create a presumption of liability, either civil or criminal, on the part of a pharmacist duly licensed under Chapter 4 of Title 26, who in good faith fills a prescription drug order presented by a patient pursuant to this Rule which was issued by an APRN pursuant to an approved nurse protocol agreement.

(a) A pharmacist shall presume that the prescription drug order was issued by an APRN duly licensed and qualified under Title 43, Chapter 34 to prescribe pharmaceutical agents.

(b) A pharmacist shall presume that the drug prescribed by the APRN is a drug approved by the delegating physician in the APRN's nurse protocol, unless the pharmacist has actual or constructive knowledge to the contrary.

(7) The APRN shall only be authorized to exercise the rights granted by O.C.G.A. § 43-34-26.3 using a prescription drug order which includes the following:

(a) The name, address, NPI number, and telephone number of the delegating physician, and the DEA number of the delegating physician if applicable;

(b) The name, address, NPI number, and telephone number of the APRN, and the APRN's DEA number if applicable;

(c) The name and address of the patient;

(d) The drug name, strength and quantity prescribed;

(e) The directions to the patient with regard to how the medication is to be administered;

(f) The number of authorized refills, if any;

(g) Such prescription drug order form shall be valid only if signed by the APRN;

(h) A prescription drug order which is transmitted either electronically or via facsimile shall conform to the requirements set out in paragraphs (1) and (2) of subsection (c) of Code Section 26-4-80, respectively.

(8) Any prescription drug order containing less information than that described in this subsection shall not be considered a legal prescription.

Al McConnell made a motion to post the revision of Rule 480-19, and Judy Gardner seconded the motion. The Board voted to post the revision of Rule 480-19.

*NOTE: Struck through text is proposed to be deleted. Underlined text is proposed to be added.

Chapter 480-19 Exempt Schedule V Over-the-Counter (OTC) Controlled Substances, Amended.

480-19-.01 Excepted Sales of Non-Pseudoephedrine Schedule V Controlled Substances.

480-19-.02 Exempt Non-Pseudoephedrine Schedule V Controlled Substances.

480-19-.03 Over-the-counter (OTC) Sales of Exempt Schedule V Controlled Substance Drug Products containing Pseudoephedrine

480-19-.04 Record keeping for Over-the-counter (OTC) Sales of Exempt Schedule V Controlled Substance Drug Products containing Pseudoephedrine

480-19-.05 Exceptions to Exempt Schedule C-V Controlled Substance Drug Products Containing Pseudoephedrine Sales

480-19-.01 Excepted Sales of Non-Pseudoephedrine Schedule V Controlled Substances.

No person shall obtain or attempt to obtain, sell, dispense or otherwise dispose of any non-pseudoephedrine substance included in Schedule V of the Georgia Controlled Substances Act, except as herein provided, and as in compliance with all other applicable laws, rules and regulations; ~~including Georgia Code Chapter 79A-8.~~ All terms used in this section shall have the same meaning as in ~~Georgia Code Chapter 79A-8~~ O.C.G.A. T. 16, Ch. 14 and T. 26, Ch. 4, as amended.

(a) A physician or medical practitioner may dispense Schedule V substances for legitimate medical purposes in the normal course of his/her professional practice. ~~A physician or medical practitioner may administer Schedule V substances in their offices but cannot charge for the dispensed drug.~~

(b) A licensed pharmacist, or intern acting under the immediate and direct supervision of a licensed pharmacist, may sell, dispense or otherwise dispose of without prescription not more than 4 oz. or 32 dosage units of an exempted non-pseudoephedrine Schedule V controlled substance within any 48 hour period of time, but only:

1. After applying reasonable means or effort to determine that such is to be used for legitimate medical purposes; and
2. After the purchaser has written his/her signature, date of birth, address, city, state and zip code upon a register which records and reflects the date of such transaction, the name, kind, quantity and intended use of such Schedule V substance sold, dispensed, or otherwise disposed of, and such records shall be maintained as required by Schedule V records.

(c) No person shall obtain or attempt to obtain, in any 48-hour period of time, more than 4 oz. or 32 dosage units of a Schedule V controlled substance.

480-19-.02 Exempt Non-Pseudoephedrine Schedule V Controlled Substances.

Before the sale of any non-pseudoephedrine Schedule V Controlled Substance without a prescription, a licensed pharmacist should first determine whether or not the product to be sold is packaged in a container with not more than 4 ounces or 32 dosage units of the drug, and whether the label provided by the product manufacturer contains a Federal Caution or Warning. If such Legend or Warning or Rx Only indication is present on the manufacturer's label, this product cannot be sold without a prescription.

480-19-.03 Over-the-counter (OTC) Sales of Exempt Schedule V Controlled Substance Drug Products containing Pseudoephedrine

(a) No person shall obtain or attempt to obtain, sell, dispense or otherwise distribute any exempt Schedule V controlled substance drug product containing pseudoephedrine as listed under O.C.G.A. 16-13-29(5), except as herein provided, and as in compliance with all other applicable state or federal laws, rules and regulations. All terms used in this section shall have the same meaning as in O.C.G.A. T.16, Ch. 13 and T. 26, Ch. 4.

1) All exempt Schedule V controlled substance pseudoephedrine containing drug products must be stored in a pharmacy's prescription department.

2) All pharmacy personnel who engage in the sale or distribution of exempt Schedule V controlled substance containing drug products must complete the DEA's self-certification training as required by the Combat Methamphetamine Epidemic Act of 2005, 21 U.S.C. 830.

(b) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist, or other designated pharmacy personnel at the direction of a registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist, may sell, dispense or otherwise dispose of without prescription not more than 3.6 grams every 24 hours, or a maximum of 9 grams every 30 days, to each customer of a pseudoephedrine containing drug product, but only:

1) After applying reasonable means or effort to determine that such is to be used for legitimate medical purposes, following the proper record keeping procedures, and ensuring the required information has been properly recorded in a logbook which contains either a written or electronic list of sales.

2) For hand-written logbooks used to record patient information before the sale of an exempt Schedule V pseudoephedrine containing drug product can take place:

(A) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist, must approve all such sales or transactions. Approval means verifying the patient's identification and ensuring the patient has a valid reason for obtaining the pseudoephedrine. After approval, the registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may direct designated pharmacy personnel, to complete any sales transactions to a patient by writing in the logbook at a minimum the name of the pseudoephedrine containing drug product, strength, and quantity sold along with the name of the patient, their date of birth, address, zip code, date and time of sale; The pharmacy may require additional patient information for the logbook as long as the required information is obtained.

(B) The patient must sign the logbook to acknowledge the sale and receipt of the pseudoephedrine containing drug product.

(C) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may personally, or may direct designated pharmacy to, ask the patient to produce a photo identification issued by a state or the federal government to use in verifying that the patient's name on the photo identification matches the name the patient wrote in the logbook; No exempt Schedule V pseudoephedrine containing drug product can be sold to a patient unless they present appropriate identification

(D) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist must or may direct designated pharmacy personnel to verify that the date and time of the sale and other information that has been entered in the logbook is correct by use of the patient's photo identification, and initial the logbook verifying the information for the sale as being correct.

3) For electronic logbooks used to record patient information for the sale of an exempt Schedule V pseudoephedrine containing drug product:

(A) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist, must approve all such sales or transactions. Approval means verifying the patient's identification and ensuring the patient has a valid reason for obtaining the pseudoephedrine. After approval, the registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may direct designated pharmacy personnel, to complete any sales transactions to a patient by entering, at a minimum, the name of the pseudoephedrine containing drug product, strength, and quantity sold; the patient's name, date of birth, address, and zip code, or entering this information may be accomplished through a point of sales system and bar code reader. The pharmacy may require additional patient information for the logbook as long as the required information is obtained.

(B) The computer for the electronic logbook can automatically enter the date and time of the sale,

(C) The patient's signature on the logbook must be captured using an electronic signature system of a type similar to or one used for credit card purchases

(D) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist may personally, or may direct designated pharmacy personnel to, must ask the patient to produce a photo identification issued by a state or the federal government to use in verifying that the patient's name on the photo identification matches the name the patient wrote in the logbook; No exempt Schedule V pseudoephedrine containing drug product can be sold to a patient unless they present appropriate photo identification

(E) A registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist must, or may direct designated pharmacy personnel to, enter their name or pharmacist, pharmacy intern license number, or pharmacy personnel's identification in the logbook to indicate the information for the sale is correct.

(4) The quantities of different strength pseudoephedrine containing drug products that equals 3.6 grams is:

Tablets/capsules - Number of tablets/capsules that equal 3.6 grams

Ingredients	Number of tablets = 3.6 grams
30 mg Pseudoephedrine HCl	146 Tablets
60 mg Pseudoephedrine HCl	73 Tablets
120 mg Pseudoephedrine HCl	36 Tablets
30 mg Pseudoephedrine Sulfate	155 Tablets
60 mg Pseudoephedrine Sulfate	77 Tablets
120 mg Pseudoephedrine Sulfate	38 Tablets
240 mg Pseudoephedrine Sulfate	19 Tablets

Liquids -Number of milliliters that equal 3.6 grams

Ingredients	Number of milliliters (ml) = 3.6 grams
6.25 mg Ephedrine HCl/ 5 ml Liquid	3515 ml
15 mg Pseudoephedrine HCl / 1.6 ml Liquid	468 ml
7.5 mg Pseudoephedrine HCl / 5 ml Liquid	2929 ml
15 mg Pseudoephedrine HCl / 5 ml Liquid	1464 ml
15 mg Pseudoephedrine HCl / 2.5 ml Liquid	732 ml
30 mg Pseudoephedrine HCl / 5 ml Liquid	732 ml
30 mg Pseudoephedrine HCl / 2.5 ml Liquid	366 ml
60 mg Pseudoephedrine HCl / 5 ml Liquid	366 ml

(c) No registered pharmacist, or pharmacy intern or pharmacy extern acting under the direct supervision of a registered pharmacist can knowingly sell more than 9 grams of pseudoephedrine to a patient in a 30 day period of time.

(1) The quantities of different strength pseudoephedrine containing drug products that equals 9 grams is:

Tablets/capsules - Number of tablets/capsules that equal 9 grams

Ingredients	Number of tablets = 9 grams
30 mg Pseudoephedrine HCl	366 Tablets
60 mg Pseudoephedrine HCl	183 Tablets
120 mg Pseudoephedrine HCl	91 Tablets
30 mg Pseudoephedrine Sulfate	389 Tablets
60 mg Pseudoephedrine Sulfate	194 Tablets
120 mg Pseudoephedrine Sulfate	97 Tablets
240 mg Pseudoephedrine Sulfate	48 Tablets

Liquids -Number of milliliters in 9 grams

Ingredients	Number of milliliters (ml) = 9 grams
6.25 mg Ephedrine HCl / 5 ml Liquid	8788 ml
15 mg Pseudoephedrine HCl / 1.6 ml Liquid	1171 ml
7.5 mg Pseudoephedrine HCl / 5 ml Liquid	7323 ml
15 mg Pseudoephedrine HCl / 5 ml Liquid	3661 ml
15 mg Pseudoephedrine HCl / 2.5 ml Liquid	1830 ml
30 mg Pseudoephedrine HCl / 5 ml Liquid	1830 ml
30 mg Pseudoephedrine HCl / 2.5 ml Liquid	915 ml
60 mg Pseudoephedrine HCl / 5 ml Liquid	915 ml

(d) All logbooks must be retained for a minimum period of 2 years from the date of the last recorded sale.

(e) Logbooks must be kept in a secure location in the pharmacy and information contained in a logbook can be shared:

(A) To comply with state or federal laws and rules;

(B) For a product recall

(C) With local, state, and federal law enforcement officers, to allow logbook information to be inspected, copied.

(f) Nothing in this rule would prohibit pharmacies, or 3rd party information technology company acting on behalf of a pharmacy, to report or transmit sales data for exempt Schedule V controlled substance drug products containing pseudoephedrine to the state operated central registry, also known as the Georgia Methamphetamine Information System (GMIS). Without approval from GDNA, such data cannot be reported to any other central record keeping system. These sales may be reported to the registry either electronically, by means of transmitting a faxed copy of a handwritten logbook, or by sending copies of handwritten logbooks to the GDNA designated collection location for the registry via the U.S. mail or other similar means.

- (1) Such prescriptions dispensed according to board of pharmacy rule 480-28 should be filed and maintained in the manner set forth for Schedule III, IV or V controlled substance prescriptions.

The Board discussed privacy concerns and the transaction fees regarding Baxa – DoseEdge; deciding to table the issue until the next meeting for further discussion.

A review of the Institute for the Certification of Pharmacy Technicians (ICPT) exam for Certification of Pharmacy Technicians (ExCPT) was discussed. Tony Moye motioned to recognize programs that are National Commission for Certifying Agencies (NCCA) accredited; Bill Prather seconded the motion and the Board voted to recognize programs that are National Commission for Certifying Agencies (NCCA) accredited.

Target Pharmacy Corporation submitted a letter of support for ExCpt. The Board views the letter as informational.

Steve Wilson mentioned GSHP annual meeting will take place October 7-9, 2011 at Brasstown Valley Resort in Young Harris, GA. Further, the GSHP summer meeting will take place July 20-22, 2012 at Amelia Island Plantation. Keep these events in mind when creating the 2012 calendar.

Al McConnell discussed clarifying if purchasing the pharmacy wall certificate is mandatory; pointing out that requiring it to be posted is not proof of current status, but the state issued blue color licensing card is proof of current status.

All Immunization Protocol reports by Walgreens were referred to the Medical Board and deemed unnecessary for viewing by the Pharmacy Board. The Walgreens representative stated that he would ensure these were sent to the Medical Board.

Allen K. Arhin; Aratiben Makken; Brenda K. Amburn; Cathyan Julien; Chintan C. Javia; Cynthia D. Autry; Elizabeth D. Jones; Janet D. Black; Odalyn G. Sheffield; Tanya Hutchens; and Wanda S. Seymour submitted a waiver request of the requirement that a Pharmacy Technician must have a high school diploma or GED. Bill Prather made a motion to grant the waiver requests, Ronnie Wallace seconded the

motion and the Board voted to grant the waiver requests because the applicants were working as technicians at the time that the law and rules were enacted.

Jessica Smith submitted a request for approval to obtain pharmacy intern hours in a non-typical setting. Ronnie Williams made a motion to approve one hour of credit for every two hours worked; Fred Barber seconded the motion, and the Board voted to approve the request.

Keri Roland submitted a request for approval that her experience as a pharmacy technician count toward her intern hours. Al McConnell made a motion to deny her request, Bill Prather seconded the motion and the Board voted to deny the request for pharmacy technician experience to count toward required intern hours.

Rahual K. Gunturi submitted a request for approval to obtain pharmacy intern hours in a non-typical setting. Ronnie Williams made a motion to approve one hour of credit for every two hours worked; Fred Barber seconded the motion, and the Board voted to approve the request.

Rehan Ishan requests an appearance with the Board regarding reinstatement of her pharmacist license. Bill Prather made a motion to grant him an appearance; Tony Moye seconded the motion. The Board voted to grant her an appearance.

Stephen Proffitt requests an appearance with the Board regarding reinstatement of his pharmacist license. Bill Prather made a motion to deny him an appearance until he submits an application; Tony Moye seconded the motion. The Board voted to deny him an appearance until he submits and application.

Johnson & Johnson requests an appearance with the Board regarding Jansson Connect trained healthcare professionals. The Board denied the appearance request stating no appearance was needed. They need to follow the law.

Curtis Pharmacy, Inc. requests an appearance with the Board regarding unit-to-unit compounding kits. The Board denied the appearance request stating that Curtis Pharmacy, Inc. must have a Georgia wholesaler license to ship into Georgia.

Bill Fixler submitted a letter requesting compounding clarification. Rick Allen of GDNA stated his agency is handling this submission.

James D. Wheeler submitted a request that the supervised practice restriction be lifted from his license. Fred Barber made a motion to grant the request and lift the supervised practice restriction from the license; Al McConnell seconded the motion and the Board voted to lift the supervised practice restriction from the license.

Emelia Orubele submitted request to lift probation status from her license. Judy Gardner made a motion to deny the request to lift probation, Bill Prather seconded the motion and the Board voted to deny the request to lift probation.

Michael A. Powell requests an appearance with the Board regarding the denial for reinstatement of his pharmacist license. Bill Prather made a motion to grant him an appearance; Tony Moyer seconded the motion. The Board voted to grant him an appearance.

Senior Assistant Attorney General, Janet B. Wray recommended the Board discuss the law Rx security paper that goes into effect October 1, 2011. She insisted the Board must create a seal and policy prior to adjournment of the meeting.

Tony Moyer made a motion to approve the following policy and seal for the tamper resistant prescription paper, Al McConnell seconded the motion and the Board adopted the following policy regarding the Board's seal for tamper resistant prescription paper:

Reference OCGA 26-4-80.1

Description of SEAL: The SEAL shall contain 'GEORGIA STATE BOARD OF PHARMACY SEAL OF APPROVAL' all in accordance with the sample shown below.

The SEAL shall comply in all respects with the sample below, including size and format.

It shall be 1 ¼ inches in diameter with Georgia type font and size as indicated: Georgia State Board of Pharmacy Seal of Approval. In the center of the seal the symbol 'Rx' black, 16pt.

Description of SEAL: The SEAL shall contain the words GEORGIA STATE BOARD OF PHARMACY SEAL OF APPROVAL in accordance with the sample shown below. The SEAL shall comply in all respects with the sample below, including size and format. It shall be 1 ¼ inches in diameter with type font and size as indicated: Georgia State Board of Pharmacy Seal of Approval, Georgia font, 7 pt.; with the Symbol 'Rx' Georgia font black, 16 pt. in the center of the seal.

The seal shall appear on the bottom right hand corner of the front of the prescription paper.

SAMPLE OF SEAL



Judy Gardner, Bill Prather, and Rick Allen were assigned to a subcommittee for the security prescription paper that goes into effect October 1, 2011.

GDNA Report: Rick Allen reported that a \$400,000 grant had been approved for a two year PMP program.

Executive Director's Report: The new Executive Director of the Pharmacy Board, Eric Lacefield, starts September 16, 2011. He will be present for the next scheduled Pharmacy Board meeting.

Miscellaneous

Bill Prather reviewed the following continuing education providers and made the following recommendations for approval:

2011-0025	Maltagon 2011 (Rick Allen, Director - GDNA)	Various Topics	8
2011-0026	Dr. Comfort	Certified Fitter of Therapeutic Shoes	8

Chairperson Steve Wilson thanked Rick Allen, Tony Moye, and Julie Barber for their dedication and hard work for a successful MALTAGON.

Chairperson Steve Wilson congratulated Lisa Durden on her recent promotion to Director of the Professional Licensing Boards Division and thanked her for all her hard work with the Pharmacy Board.

The meeting adjourned at 6:15 p.m.

The next Pharmacy Board meeting will be Wednesday, October 12, 2011 at 10:00 a.m. at the Office of the Professional Licensing Boards, 237 Coliseum Drive, Macon, Georgia 31217.

Steve Wilson, President
The Georgia State Board of Pharmacy

Date

Lisa Durden, Executive Director
The Georgia State Board of Pharmacy

Date